Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, cilt.7, ss.2790-2815, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 7
- Basım Tarihi: 2019
- Doi Numarası: 10.1016/j.jaip.2019.06.011
- Dergi Adı: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.2790-2815
- Çukurova Üniversitesi Adresli: Evet
Özet
BACKGROUND: LPS-responsive beige-like anchor (LRBA) deficiency presents with susceptibility to infections, autoimmunity, and lymphoproliferation. The long-term efficacy of cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (abatacept) as targeted therapy for its immune dysregulatory features remains to be established.